# X4 Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/x4-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.x4pharma.com
- Total disclosed funding: $99M
- Latest round: Series B (Sep 21, 2018)
- Investors on record: 7

## About

Established in 2012 and based in Boston, US, X4 Pharmaceuticals is a biopharmaceutical company that focuses on developing and marketing drugs for immune system dysfunction disorders. The headquartered in Boston, Massachusetts with a research center of excellence in Vienna, Austria. Dr. Ragan, the company's CEO and president, received her bachelor's degree from Tufts University and her doctorate from the Massachusetts Institute of Technology. She previously served as Chief Commercial Officer at Lysosomal Therapeutics. 

In March 2019, X4 Pharmaceuticals merged with Arsanis, Inc. (Nasdaq: ASNS). The reverse merger resulted in a combined company operating under the X4 Pharmaceuticals name which commenced trading on the Nasdaq Capital Market under the symbol XFOR and that will focus on the development and commercialization of X4’s lead product candidate, X4P-001, and the advancement of X4’s pipeline of treatments for rare diseases of the immune system and rare cancers. Additionally, in May 2023, New Enterprise Associates, Bain Capital, Adage Capital Management, Stonepine Capital Management, Acorn Bioventures, OrbiMed Advisors, Kingdon Capital and other unspecified investors greed to acquire X4 Pharmaceuticals for USD 65 million.

The company focuses on developing drugs for rare diseases and immune system function. Its self-developed products include Mavorixafor and X4P-002. The Mavorixafor for the treatment of WHIM syndrome and waldenströms macroglobulinemia.

## Funding rounds

- Series B, Sep 21, 2018, $35M — NeoMed, Emerging Technology Partners, Hercules Capital, Cormorant Asset Management, Thynk Capital
- Series B, Nov 16, 2017, $27M — OrbiMed Advisors, Emerging Technology Partners, Bill & Melinda Gates Foundation, Cormorant Asset Management, Thynk Capital
- Series A, Dec 14, 2015, $38M — Cormorant Asset Management

## Investors

- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Emerging Technology Partners (https://capitalatlas.ai/funds/emerging-technology-partners) — Series B
- Bill & Melinda Gates Foundation — Series B
- Thynk Capital (https://capitalatlas.ai/funds/thynk-capital) — Series B
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series B
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series B